AMARANTUS BIOSCIENCE HLDG Press Releases

AMBS 
$0.084
*  
-0.0039
-4.44 %
Get AMBS Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading AMBS now


Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015
12/23/2014 4:01:00 PM - Business Wire


Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
12/23/2014 4:00:00 PM - GlobeNewswire


Amarantus Commences Launch of Proprietary Alzheimer''s Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
12/22/2014 7:00:00 AM - GlobeNewswire


Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
12/19/2014 7:35:00 AM - GlobeNewswire


Amarantus Announces Second Closing of Series E Preferred Financing
12/19/2014 7:00:00 AM - GlobeNewswire


Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
12/11/2014 8:00:00 AM - GlobeNewswire


Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
12/8/2014 8:00:00 AM - GlobeNewswire


Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
11/25/2014 9:17:00 AM - GlobeNewswire


Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014
11/24/2014 8:00:00 AM - GlobeNewswire


Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer''s Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
11/20/2014 8:00:00 AM - GlobeNewswire


Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
11/17/2014 4:05:00 PM - GlobeNewswire


Amarantus to Host Business Update Conference Call on November 18, 2014
11/17/2014 8:00:00 AM - GlobeNewswire


Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
11/10/2014 6:00:00 AM - GlobeNewswire


Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
10/20/2014 8:00:00 AM - GlobeNewswire


Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
10/16/2014 9:30:00 AM - GlobeNewswire


Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
10/9/2014 6:00:00 AM - GlobeNewswire


Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
10/7/2014 8:00:00 AM - GlobeNewswire


Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson''s Disease Levodopa-Induced Dyskinesia Clinical Trial
9/29/2014 2:03:00 PM - GlobeNewswire